[Prostaglandin E1 in therapy of peripheral arterial occlusive disease].
The intraarterial and intravenous infusion of prostaglandin E1 (PGE1) today is well established in the therapy of peripheral arterial occlusive disease. This review summarizes the results of pharmacological-clinical studies and the influence of PGE1 on the pathomechanism of ischaemia due to its antithrombotic, leukocyte and endothelial stabilizing properties. Clinical data available on continuous and intermittent infusion for both modes of administration are critically appraised, taking into account more recent data on active metabolites.
Sinzinger
H
H
Wilhelm Auerswald-Atheroskleroseforschungsgruppe Wien, Bundesrepublik Deutschland.
Rogatti
W
W
D000527:Alprostadil / Q000008:administration & dosage*; D001157:Arterial Occlusive Diseases / Q000097:blood / Q000628:therapy*; D004730:Endothelium, Vascular / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D015539:Platelet Activation / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects
D000527:Alprostadil
Prostaglandin E1 in der Therapie der peripheren arteriellen Durchblutungsstörung.